Arcutis Biotherapeutics, Inc. ARQT Long-term debt, gross
Long-term debt, gross at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtInstrumentCarryingAmount.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s long-term debt, gross.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s long-term debt, gross?
- Arcutis Biotherapeutics, Inc. (ARQT) reported long-term debt, gross of $100M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s long-term debt, gross changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s long-term debt, gross decreased by 0.0% year-over-year, from $100M to $100M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s long-term debt, gross?
- Over 4 years (2021 to 2025), Arcutis Biotherapeutics, Inc.'s long-term debt, gross has grown at a 7.5% compound annual growth rate (CAGR), from $75M to $100M.